Tuesday February 25, 2020

More Cases of Measles Reported in US, the Worst Outbreak in Over 25 Years

Nearly 30 states have reported cases, with outbreaks of over three cases ongoing in California

0
//
Measles, US, Outbreak
A poster released by Los Angeles County Department of Public Health is seen as experts answer questions regarding the measles response and the quarantine orders in Los Angeles, April 26, 2019. VOA

Thirty-three new cases of measles were reported last week, with 1,077 active cases total within the United States, according to health officials — the worst outbreak in over 25 years, when 2,126 cases were recorded in 1992.

Nearly 30 states have reported cases, with outbreaks of over three cases ongoing in California, New York, Pennsylvania and Washington state. New York’s Rockland County declared a state of emergency in late May, over a outbreak in an ultra-Orthodox Jewish community.

Measles was declared eradicated within the U.S. in 2000, four decades after elimination was first announced as a goal. A disease is considered eliminated when a full year passes with no active transmissions. If the current outbreak isn’t under control by October 2019, the U.S. will lose its measles elimination status.

“That loss would be a huge blow for the nation and erase the hard work done by all levels of public health,” the Centers for Disease Control (CDC) said in a press release last month. “Before widespread use of the measles vaccine, an estimated 3 to 4 million people got measles each year in the United States, along with an estimated 400 to 500 deaths and 48,000 hospitalizations.”

Measles, US, Outbreak
Thirty-three new cases of measles were reported last week. Pixabay

According to the agency, most cases are being spread by unvaccinated school-age children. Communities with low rates of vaccination create pockets through which the disease can easily be spread.

“I want to reassure parents that vaccines are safe, they do not cause autism,” said CDC Director Robert Redfield, M.D., in the press release. “The greater danger is the disease the vaccination prevents.”

Also Read- ndia Struggles with Encephalitis Outbreak in Eastern State of Bihar, One of Its Poorest Regions

Travel from countries where measles is common, especially Ukraine, Israel and the Philippines, is also contributing to the U.S. outbreaks, according to the Associated Press. (VOA)

Next Story

American Biotech Company Works with Chinese Officials to Test Drug Against Coronavirus

Trials to Test Ebola Drug's Potential to Prevent, Treat Coronavirus

0
Coronavirus
An American biotech company says it is working with Chinese authorities to determine the efficiency of a drug that can fight coronavirus. Pixabay

By Natalie Liu

An American biotech company says it is working with Chinese authorities to determine whether the antiviral drug remdesivir may provide an effective treatment for victims of the fast-spreading coronavirus known as COVID-19. The Chinese researchers hope to have the answer by May 1.

Officials of Gilead Sciences, which invented remdesivir as a treatment for Ebola and another disease, told VOA the company has initiated two clinical trials among infected patients “to determine the safety and efficacy of remdesivir as a potential treatment for the coronavirus.”

The trials have been warmly welcomed in China, where the nation’s official news agency celebrated the launch with a front page article. Anxious Chinese citizens have noted that the four syllables of remdesivir resemble the phrase as renmin-de-xi-wang, or people’s hope.

Coronavirus
A medical worker holds a thermometer to check a passenger’s temperature at a checkpoint as the country is hit by an outbreak of the coronavirus in Susong County, Anhui province, China. VOA

There are also more scientific reasons to be hopeful, including the case of an American coronavirus patient who experienced a speedy recovery in January, just 24 hours after being given remdesivir. Before the drug was administered, his symptoms had shown signs of worsening.

The first trial began enrolling patients on February 6, said a written statement from Gilead, which says it has provided China with “enough doses of remdesivir to treat up to 500 trial participants.” A Shanghai-based media outlet reported having seen a customs clearance form showing that 2,843 boxes of remdesivir arrived in Beijing on February 4.

The next day, a conference dedicated to the official launch of clinical trials took place at the Jinyintan Hospital in Wuhan, led by Dr. Bin Cao and his colleague Dr. Chen Wang, both top scientists practicing at the China-Japan Friendship Hospital in Beijing. Jinyintan Hospital has been treating some of the most critical COVID-19 cases since the outbreak began.

Gilead confirmed the trials are “being coordinated by the China-Japan Friendship Hospital in Beijing.” A filing registered with the U.S. National Library of Medicine lists the Beijing-based Capital Medical University as the trial’s main sponsor and Cao, a specialist in pulmonary critical care at the China-Japan Friendship Hospital, as the “responsible party.”

Research shows promise

In a scientific paper based on animal studies and published last week, scientists found remdesivir to be effective both for the prevention and treatment of the deadly Middle East Respiratory Syndrome coronavirus (MERS-CoV,) which is known to bear resemblances to COVID-19.

“Remdesivir prevented disease when administered before infection and improved the condition of macaques [monkeys] when given after the animals already were infected,” said scientists at the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Laboratories in Hamilton, Montana.

Coronavirus
A medical worker calls his colleague inside an isolated ward at Jinyintan Hospital in Wuhan, the epicenter of the novel coronavirus outbreak, in Hubei province, China. VOA

Dr. Emmie de Wit, Chief of the Molecular Pathogenesis Unit in the Laboratory of Virology at the Montana facility, told VOA that she and her colleagues conducted their studies and submitted their results for review “well before the world knew of the outbreak in Wuhan.” De Wit said she and her colleagues learned about the coronavirus outbreak on Dec. 31.

Wuhan trials

In the Wuhan study, participants are divided into two groups — those “who have developed more severe clinical manifestations” such as requiring oxygen, and those who do not require oxygen.

“Patients will receive 10 days of intravenously administered remdesivir. The primary endpoint of both studies involves clinical improvement 28 days after treatment,” according to Gilead. Cao reported that 200 mg of remdesivir would be given to a group of patients on day one, followed by 100 mg once-daily “maintenance doses” for nine additional days.

Also Read- Russia Allows Chinese Nationals with Business Visas Despite Entry Ban

Patients in a control group were to be given placebos. To ensure objectivity, the identities of the patients receiving the placebos are masked from the participants, care providers, researchers and outcome assessors.

The researchers say they aim to complete the trials by April 3 and evaluate the results by May 1. (VOA)